Patents Assigned to VIB
  • LIVER-SPECIFIC NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USE THEREOF
    Publication number: 20110184049
    Abstract: The present invention relates to nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy.
    Type: Application
    Filed: April 21, 2009
    Publication date: July 28, 2011
    Applicants: VIB VZW, Life Sciences Research Partners VZW, Universiteit Gent
    Inventors: Marinee Chuah, Thierry Vandendriessche, Pieter De Bleser
  • Method of treating cancer by combination therapy using TNF and alpha-galactosylceramide
    Patent number: 7959907
    Abstract: The invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of TNF and alfa-galactosylceramide.
    Type: Grant
    Filed: February 20, 2008
    Date of Patent: June 14, 2011
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Peter Brouckaert, Dirk Elewaut, Leander Huyghe
  • Promoter mutations that increase amyloid precursor protein expression
    Patent number: 7960117
    Abstract: The present invention relates to mutations in the amyloid precursor protein (APP) promoter region, whereby the mutations cause a significant increase in APP expression. The increase in APP expression is related to Alzheimer's disease, and the mutations can be used in Alzheimer's disease diagnosis, or in the construction of transgenic animal models for studying Alzheimer's disease.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: June 14, 2011
    Assignees: VIB VZW, Universiteit Antwerpen
    Inventors: Christine van Broeckhoven, Jessie Theuns
  • DIAGNOSTIC TEST FOR THE DETECTION OF EARLY STAGE LIVER CANCER
    Publication number: 20110136240
    Abstract: The invention provides methods and kits to detect early stage hepatocellular carcinoma or a change in the gradation of hepatocellular carcinoma in mammals. The diagnostic marker is based on the profiling and identification of diagnostic carbohydrates present in a body fluid such as blood serum.
    Type: Application
    Filed: June 11, 2008
    Publication date: June 9, 2011
    Applicants: VIB VZW, UNIVERSITEIT GENT
    Inventors: Cuiying Chen, Roland H. Contreras
  • BLOOD SERUM MARKER FOR DETECTION AND DIAGNOSIS OF ALZHEIMER'S DISEASE
    Publication number: 20110100816
    Abstract: The present invention relates to a blood marker for early detection and diagnosis of Alzheimer's disease. More specifically, it relates to an analysis of the protein glycan profile in the blood, and the identification of specific peak ratio's when compared to healthy aged matched subjects that are typical for Alzheimer's dementia.
    Type: Application
    Filed: June 10, 2009
    Publication date: May 5, 2011
    Applicants: UNIVERSITEIT GENT, VIB VZW
    Inventors: Cuiying Chen, Claude Libert
  • USE OF SIP1 AS DETERMINANT OF BREAST CANCER STEMNESS
    Publication number: 20110104183
    Abstract: The present invention relates to the diagnosis and treatment of cancer. More specifically, it relates to the use of SIP1 nucleic acid and/or protein for the detection of breast cancer stem cells, and the repression of the gene and/or the inactivation of the protein to repress the differentiation of cells into cancer cells and to inhibit metastasis of breast cancer tumors.
    Type: Application
    Filed: February 26, 2009
    Publication date: May 5, 2011
    Applicants: VIB VZW, UNIVERSITEIT GENT
    Inventors: Geert Berx, Cindy Vandewalle, Eric Raspe
  • METHODS FOR PRODUCING SUBSTANTIALLY HOMOGENEOUS HYBRID OR COMPLEX N-GLYCANS IN METHYLOTROPHIC YEASTS
    Publication number: 20110092374
    Abstract: The present invention provides methods for effectively and efficiently converting methylotrophic yeast's heterogeneous high mannose-type N-glycosylation to mammalian-type N-glycosylation by disruption of an endogenous glycosyltransferase gene (OCH1) and step-wise introduction of heterologous glycosidase and glycosyltransferase activities. Each engineering step includes a number of stages: transformation with an appropriate vector, cultivation of a number of transformants, performance of sugar analysis and heterologous protein expression analysis, and selection of a desirable clone. The selected clone is then subjected to the next engineering step.
    Type: Application
    Filed: October 18, 2010
    Publication date: April 21, 2011
    Applicants: VIB, VZW, UNIVERSITEIT GENT, RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: Nico Callewaert, David A. Wiersma
  • NOVEL CRUSTACEAN ANDROGENIC GLAND HORMONE
    Publication number: 20110065638
    Abstract: The present invention relates to a novel crustacean androgenic gland hormone. More specifically, the invention relates to an androgenic gland hormone derived from Penaeus monodon. The invention relates further to the use of the hormone to influence the sex ratio in prawn and shrimp cultures, and to set up monosex cultures. It is also related to the use of the hormone and its gene or fragments thereof in sex determination.
    Type: Application
    Filed: March 5, 2009
    Publication date: March 17, 2011
    Applicants: VIB VZW, Universiteit Gent, Moana Belgium NV
    Inventors: Frank Van Breusegem, Jan Staelens, Marnik Vuylsteke
  • Treatment of EGFR-dependent tumors by ABIN (a20 -binding inhibitor of NF kappab)
    Patent number: 7893026
    Abstract: The present invention relates to the treatment of epidermal growth factor-family receptor- (ErbB-) dependent tumors. More specifically, the present invention relates to the use of ABIN for the preparation of a medicament to inhibit epidermal growth factor- (EGF-) induced proliferation, and to treat ErbB-dependent tumors.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: February 22, 2011
    Assignees: VIB VZW, Universiteit Gent, Vrije Universiteit Brussel
    Inventors: Rudi Beyaert, Hilde Revets, Lieven Huang
  • Novel Vaccine Against Trypanosoma Cruzi Infection
    Publication number: 20110038887
    Abstract: The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to a recombinant mutant trans-sialidase enzyme that can be used as an efficient vaccine, without side effects.
    Type: Application
    Filed: March 14, 2007
    Publication date: February 17, 2011
    Applicants: VIB VZW, UNIVERSITEIT GENT
    Inventors: Roland Contreras, Kristof De Vusser, Silvia Revelli
  • NUCLEIC ACIDS OF PICHIA PASTORIS AND USE THEREOF FOR RECOMBINANT PRODUCTION OF PROTEINS
    Publication number: 20110021378
    Abstract: The present invention provides the genome sequence of Pichia pastoris and manually curated annotation of protein-coding genes. The invention provides novel nucleic acids, proteins, and related expression vectors useful for genetic engineering of methylotrophic yeast strains, as well as engineered methylotrophic yeast strains particularly Pichia pastsoris, and use thereof for recombinant production of heterologous proteins including glycoproteins suitable for use in mammals including humans.
    Type: Application
    Filed: May 21, 2010
    Publication date: January 27, 2011
    Applicants: RESEARCH CORPORATION TECHNOLOGIES, VIB, VZW, UNIVERSITEIT GENT
    Inventors: Nico Callewaert, Kristof De Schutter, Petra Tiels, Yao-Cheng Lin
  • Treatment of liver cirrhosis and its complications
    Patent number: 7867490
    Abstract: The present invention relates to the field of liver diseases, more particularly to the field of portal hypertension and liver cirrhosis. The invention relates to the use of molecules which can inhibit the binding of placental growth factor (PIGF) to its receptor (VEGFR-1), such as monoclonal antibodies, for the manufacture of a medicament to treat liver cirrhosis, portal hypertension and its complications.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: January 11, 2011
    Assignees: VIB VZW, Life Sciences Research Partners VZW, Universiteit Gent
    Inventors: Peter Carmeliet, Isabelle Colle, Anja Geerts
  • Inhibitors of prolyl-hydroxylase-1 for the treatment of skeletal muscle degeneration
    Patent number: 7858593
    Abstract: The invention relates to the field of muscle pathologies, more particularly to the field of diseases where skeletal muscle degeneration occurs. The invention describes transgenic mice that do not produce prolyl-hydroxylase-1, -2 or -3. It is revealed that the phenotype of the prolyl-hydroxylase 1 knock-out mouse is characterized by a protection of skeletal muscle atrophy due to a variety of muscle damages, especially ischemic insults. The invention thus relates to the use of molecules that can bind to prolyl-hydroxylase-1 for the prevention and/or treatment of skeletal muscle degeneration.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: December 28, 2010
    Assignees: VIB VZW, Life Sciences Research Partners VZW
    Inventors: Peter Carmeliet, Julián Aragonés López
  • B CELL TOLERANCE INDUCTION
    Publication number: 20100322967
    Abstract: The present invention relates to the induction of immune tolerance, by a novel method of induction of IL-10 production in B cells, whereby said B cells can be loaded with antigen before, during or after the induction of the IL-10 production. More specifically, the invention relates to the transduction of the B cell with a retroviral vector encoding an antigen, whereby the retroviral envelop induces IL-10 production in the B cell by activation the TLR2 receptor, in combination with its viral receptor.
    Type: Application
    Filed: October 8, 2008
    Publication date: December 23, 2010
    Applicants: Life Sciences Research Partners VZW, VIB VZW
    Inventors: Thierry Vandendriessche, Marinee Chuah, Jean-Marie Saint-Remy, Marc Jacquemin
  • Modulation of plant cell number
    Patent number: 7829758
    Abstract: The present invention relates to the use of the ANG4 gene, or a variant thereof, to modulate the cell number of a plant organ. Said modulation can be used to increase the plant biomass, or to adapt the plant architecture.
    Type: Grant
    Filed: August 16, 2005
    Date of Patent: November 9, 2010
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Gerda Cnops, Delphine Fleury, Dirk G. Inze, Maria van Lijsebettens
  • PROTEIN GLYCOSYLATION MODIFICATION IN METHYLOTROPHIC YEAST
    Publication number: 20100267084
    Abstract: The present invention provides genetically engineered strains of Pichia capable of producing proteins with reduced glycosylation. In particular, the genetically engineered strains of the present invention are capable of expressing either or both of an ?-1,2-mannosidase and glucosidase II. The genetically engineered strains of the present invention can be further modified such that the OCH1 gene is disrupted. Methods of producing glycoproteins with reduced glycosylation using such genetically engineered stains of Pichia are also provided.
    Type: Application
    Filed: April 16, 2009
    Publication date: October 21, 2010
    Applicants: VIB, VZW, RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: Roland Contreras, Nico L. M. Callewaert, Steven C. J. Geysens
  • Episomal fusion gene
    Patent number: 7776534
    Abstract: The present invention relates to an episomal structure expressing a functional oncogene, whereby said oncogene is a fusion gene of two chromosomal gene fragments. More specifically, the invention relates to a NUP214-ABL1 fusion product, important in the development of T-cell acute lymphoblastic leukemia, to methods to detect the fusion and to methods to prevent the oncogenic activity of said fusion product.
    Type: Grant
    Filed: June 7, 2005
    Date of Patent: August 17, 2010
    Assignees: VIB VZW, K.U. Leuven Research and Development
    Inventors: Jan Cools, Anne Hagemeijer, Peter Marynen
  • OLIGONUCLEOTIDE COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
    Publication number: 20100204309
    Abstract: The invention relates to the identification of microRNAs whose expression is diminished in neurodegenerative disorders. In particular, the identified microRNAs can be used for the downregulation of the beta-secretase (BACE1) in mammalian brain and hence for the treatment of Alzheimer's disease.
    Type: Application
    Filed: April 21, 2008
    Publication date: August 12, 2010
    Applicants: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R & D
    Inventors: Sébastien Hérbert, Bart De Strooper
  • NON-STEROIDAL BRASSINOSTEROID MIMETIC
    Publication number: 20100152253
    Abstract: The present invention relates to non-steroidal mimetics of brassinosteroids. More specifically, it relates to non-steroidal monocyclic compounds, capable of rescuing the brassinosteroid receptor null mutation bri1-116. Preferably, said compounds are low molecular weight, monocyclic halogenated compound.
    Type: Application
    Filed: October 9, 2007
    Publication date: June 17, 2010
    Applicants: VIB VZW, Universiteit Gent
    Inventors: Dominique Audenaert, Tom Beeckman, Bert De Rybel, Jenny Russinova, Dirk G. Inze
  • Use of placental growth factor for treating ischemic muscle disease
    Patent number: 7727971
    Abstract: The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.
    Type: Grant
    Filed: June 21, 2006
    Date of Patent: June 1, 2010
    Assignees: Life Sciences Research Partners VZW, Flanders Interuniversity Institute for Biotechnology (VIB)
    Inventors: Peter Carmeliet, Désiré Collen